Mobile

HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease(Protocol DIM20EXT)

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-018123-32

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To evaluate the long-term safety of dimebon (latrepirdine) in Huntington disease (HD) subjects who have successfully completed 26 weeks of blinded treatment in the HORIZON protocol (DIM20).

Critère d'inclusion

  • Huntington`s Corea

Liens